John Rex Email and Phone Number
John Rex work email
- Valid
- Valid
- Valid
- Valid
- Valid
- Valid
John Rex personal email
- Valid
- Valid
- Valid
John Rex phone numbers
I am a physician and drug developer with more than 30 years of development and policy experience focused on antimicrobial agents. My development experience includes moving compound opportunities from early preclinical development through all later stages of development in the context of (a) academic training and faculty positions (NIH, Bethesda, MD; Univ. of Texas Medical School-Houston), (b) an internal role at a multinational pharmaceutical firm (AstraZeneca Pharmaceuticals), (c) board-level roles in two biotech firms (F2G Ltd, Adenium Biotech ApS, and (d) an operating partner role with a venture capital investment group (Advent Life Sciences). In parallel and via multiple cross-industry initiatives, I have actively driven changes to the global regulatory and policy environment for antimicrobial agents. I am one of the two Industry-based cofounders of the Innovative Medicines Initiative’s New Drugs for Bad Bugs (ND4BB) program bringing Industry and Academic collaborators together on a range of antibiotic discovery and development projects. I currently also serve on the US Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria and am an Expert-in-Resident at Wellcome Trust, London, UK.
Amr.Solutions
View-
Editor-In-ChiefAmr.Solutions Feb 2017 - PresentMassachusetts, Us
-
Chief Medical OfficerF2G Jun 2021 - PresentManchester, England, GbBased in Manchester, UK, F2G Ltd is dedicated to discovery and development of clinically superior drug classes to treat life-threatening systemic fungal infections in at-risk patient populations. As Chief Medical Officer, I actively lead the clinical development program. -
Chief Medical Officer And DirectorF2G Nov 2016 - Jun 2021Manchester, England, GbBased in Manchester, UK, F2G Ltd is dedicated to discovery and development of clinically superior drug classes to treat life-threatening systemic fungal infections in at-risk patient populations. As Chief Medical Officer and Director, I actively lead the clinical development program and work as part of the Board of Directors on long-term company strategy.
-
Non-Executive DirectorF2G Sep 2012 - Oct 2016Manchester, England, GbBased in Manchester, UK, F2G Ltd is dedicated to discovery and development of clinically superior drug classes to treat life-threatening systemic fungal infections in at-risk patient populations. At F2G, I both work with the Board on long-term company strategy and I also actively direct F2G’s scientific agenda via membership in the Board’s science committee.
-
Consultant And Operating PartnerAdvent Life Sciences Llp Nov 2015 - PresentLondon | Investing Transatlantically, GbAdvent Life Sciences is an investor in F2G, Ltd. -
Adjunct Professor Of Medicine, University Of Texas Medical School-HoustonThe University Of Texas Health Science Center At Houston Jan 2003 - PresentHouston, Texas, Us -
Professor Of Medicine, University Of Texas Medical School-HoustonThe University Of Texas Health Science Center At Houston Jul 1992 - Dec 2002Houston, Texas, UsAssistant Professor (July 1992 to August 1996), Associate Professor (September 1996 to August 2001), Professor (September 2001 to December 2002)
-
Expert-In-ResidenceWellcome Trust Sep 2014 - Dec 2019London, Uk, GbI provided strategic guidance to Wellcome Trust on its Drug-Resistant Infection initiatives. -
Member, Seeding Drug Discovery CommitteeWellcome Trust Jan 2011 - Dec 2016London, Uk, Gb
-
Non-Executive DirectorAdenium Biotech Aps Nov 2015 - Sep 2019Adenium Biotech is a Danish biopharmaceutical company spun out from Novozymes A/S in 2011. Adenium focuses on the development and commercialization of novel antibiotics for the treatment of multi-drug resistant bacterial infections. -
Member, Presidential Advisory Council, Action Plan For Combating Antimicrobial Resistant BacteriaU.S. Department Of Health And Human Services Sep 2015 - Dec 2018Washington, District Of Columbia, UsThe Advisory Council will provide advice, information, and recommendations to the Secretary of DHHS regarding programs and policies intended to: (1) Preserve the effectiveness of antibiotics by optimizing their use; (2) Advance research to develop improved methods for combating antibiotic resistance and conducting antibiotic stewardship; (3) Strengthen surveillance of antibiotic-resistant bacterial infections; (4) Prevent the transmission of antibiotic-resistant bacterial infections;Advance the development of rapid point-of-care and agricultural diagnostics; (5) Further research on new treatments for bacterial infections; (6) Develop alternatives to antibiotics for agricultural purposes; (7) Maximize the dissemination of up-to-date information on the appropriate and proper use of antibiotics to the general public and human and animal healthcare providers; and (8) Improve international coordination of efforts to combat antibiotic resistance. -
Chief Strategy OfficerCarb-X Jul 2016 - Sep 2017CARB-X (www.carb-x.org) is a public-private partnership providing non-equity, non-dilutive finance in support of pre-clinical development of antibacterial products. Over an initial 5-year funding cycle, CARB-X will seek to accelerate a diverse portfolio of at least 20 high-quality antibacterial products towards clinical development leveraging $250 million in BARDA funds with matching funds from the Wellcome Trust and the AMR Centre (UK). As Chief Strategy Officer, I worked with the Executive Director to design the overall portfolio strategy for this project.
-
Senior Vp And Chief Strategy Officer, Infection Business UnitAstrazeneca Nov 2015 - Oct 2016Cambridge, Cambridgeshire, GbThe AstraZeneca Infection Business Unit is a global leader in developing novel antibacterial therapies. As Chief Strategy Officer, I sought new licensing opportunities for the Business Unit, provided strategic guidance to the Business Unit, and worked to shape relevant global regulatory and payor policies. -
Senior Vp And Head Of Infection, Global Medicines DevelopmentAstrazeneca Jun 2012 - Oct 2015Cambridge, Cambridgeshire, Gb
-
Vice President Clinical InfectionAstrazeneca Jan 2003 - May 2012Cambridge, Cambridgeshire, Gb
-
Member, Nominating CommitteeClinical And Laboratory Standards Institute Apr 2013 - Mar 2016Wayne, Pennsylvania, Us -
Vice Chair, Consensus Committee On MicrobiologyClinical And Laboratory Standards Institute Jan 2013 - Dec 2015Wayne, Pennsylvania, Us
-
Chair, Consensus Committee On MicrobiologyClinical And Laboratory Standards Institute Jan 2009 - Dec 2012Wayne, Pennsylvania, Us
-
Industry Representative, Anti-Infective Drugs Advisory Committee (Aidac)Fda Nov 2007 - Oct 2011Silver Spring, Md, Us -
Editor, Antimicrobial Agents & ChemotherapyAmerican Society For Microbiology Jul 2000 - Jun 2010Washington, District Of Columbia, Us
John Rex Skills
John Rex Education Details
-
Baylor College Of MedicineMedicine -
Rice UniversityBiochemistry
Frequently Asked Questions about John Rex
What company does John Rex work for?
John Rex works for Amr.solutions
What is John Rex's role at the current company?
John Rex's current role is Chief Medical Officer, F2G, Ltd; Editor-in-Chief, AMR.Solutions; Operating Partner, Advent Life Sciences.
What is John Rex's email address?
John Rex's email address is kr****@****ail.com
What is John Rex's direct phone number?
John Rex's direct phone number is +197847*****
What schools did John Rex attend?
John Rex attended Baylor College Of Medicine, Rice University.
What are some of John Rex's interests?
John Rex has interest in Home Improvement, Home Decoration, Electronics.
What skills is John Rex known for?
John Rex has skills like Clinical Research, Drug Discovery, Biochemistry, Microbiology, Infectious Diseases, Biotechnology, Healthcare, Clinical Trials, Oncology, Chemistry, Pharmaceutical Industry, Strategic Planning.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial